ANI Pharmaceuticals (NASDAQ:ANIP) Downgraded by Zacks Research to Hold

Zacks Research lowered shares of ANI Pharmaceuticals (NASDAQ:ANIP) from a strong-buy rating to a hold rating in a research report released on Tuesday,Zacks.com reports.

A number of other equities research analysts have also commented on ANIP. Guggenheim upped their price objective on shares of ANI Pharmaceuticals from $114.00 to $115.00 and gave the company a “buy” rating in a research note on Monday, November 10th. Barclays began coverage on ANI Pharmaceuticals in a research note on Tuesday, December 9th. They set an “overweight” rating and a $100.00 target price for the company. Weiss Ratings restated a “hold (c+)” rating on shares of ANI Pharmaceuticals in a report on Monday, December 29th. Truist Financial boosted their target price on shares of ANI Pharmaceuticals from $77.00 to $90.00 and gave the company a “hold” rating in a research report on Thursday, October 9th. Finally, HC Wainwright increased their price objective on shares of ANI Pharmaceuticals from $93.00 to $121.00 and gave the stock a “buy” rating in a research report on Wednesday, September 17th. Six equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $102.14.

ANI Pharmaceuticals Trading Up 2.6%

ANIP opened at $79.47 on Tuesday. The firm has a market capitalization of $1.79 billion, a price-to-earnings ratio of 48.75 and a beta of 0.51. The company’s 50 day moving average price is $83.31 and its two-hundred day moving average price is $83.00. The company has a debt-to-equity ratio of 1.20, a current ratio of 2.58 and a quick ratio of 2.04. ANI Pharmaceuticals has a fifty-two week low of $52.74 and a fifty-two week high of $99.50.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings data on Friday, November 7th. The specialty pharmaceutical company reported $2.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.74 by $0.30. The business had revenue of $227.81 million during the quarter, compared to the consensus estimate of $211.92 million. ANI Pharmaceuticals had a return on equity of 26.73% and a net margin of 4.91%.ANI Pharmaceuticals’s quarterly revenue was up 53.6% on a year-over-year basis. During the same period in the prior year, the business posted $1.34 earnings per share. ANI Pharmaceuticals has set its FY 2025 guidance at 7.370-7.640 EPS. As a group, research analysts predict that ANI Pharmaceuticals will post 3.86 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Renee P. Tannenbaum sold 1,800 shares of the firm’s stock in a transaction dated Friday, December 5th. The shares were sold at an average price of $81.15, for a total transaction of $146,070.00. Following the transaction, the director directly owned 25,157 shares of the company’s stock, valued at $2,041,490.55. This trade represents a 6.68% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, VP Meredith Cook sold 400 shares of ANI Pharmaceuticals stock in a transaction that occurred on Friday, December 12th. The stock was sold at an average price of $82.32, for a total transaction of $32,928.00. Following the transaction, the vice president directly owned 74,874 shares in the company, valued at approximately $6,163,627.68. This represents a 0.53% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 28,001 shares of company stock valued at $2,446,934 over the last 90 days. 11.10% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On ANI Pharmaceuticals

Institutional investors have recently made changes to their positions in the stock. Advisors Asset Management Inc. bought a new stake in shares of ANI Pharmaceuticals during the 1st quarter worth $28,000. Hantz Financial Services Inc. lifted its stake in ANI Pharmaceuticals by 202.6% during the third quarter. Hantz Financial Services Inc. now owns 354 shares of the specialty pharmaceutical company’s stock worth $32,000 after purchasing an additional 237 shares during the last quarter. Caitong International Asset Management Co. Ltd lifted its position in ANI Pharmaceuticals by 4,636.4% in the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 521 shares of the specialty pharmaceutical company’s stock worth $34,000 after buying an additional 510 shares during the last quarter. Newbridge Financial Services Group Inc. increased its holdings in ANI Pharmaceuticals by 200.0% during the 2nd quarter. Newbridge Financial Services Group Inc. now owns 600 shares of the specialty pharmaceutical company’s stock valued at $39,000 after purchasing an additional 400 shares during the period. Finally, State of Wyoming bought a new position in ANI Pharmaceuticals during the 2nd quarter valued at approximately $50,000. Institutional investors own 76.05% of the company’s stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.